Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Big Drug Mergers: So They're OK, Right? | Main | For Immediate Rewording. Uh, Release. »

February 24, 2014

ACS Webinars on Drug Discovery

Email This Entry

Posted by Derek

I wanted to mention the ACS Webinar series on Drug Discovery, which will be going on every so often throughout the year. I'm going to be doing the introductory overview one, along with Rick Connell of Pfizer and Nick Meanwell of BMS, this Thursday, 2PM to 3PM EST. As you'll note from the schedule, there are plenty more of these coming up that go into more detail, so we're going to be setting the stage and taking questions from the audience.

Comments (10) + TrackBacks (0) | Category: Blog Housekeeping


COMMENTS

1. SkepticMOA on February 24, 2014 1:37 PM writes...

Should we do a webinar on what happens after neuroscience drug discovery through Phase 3 really looks like?

1) Development of promising lead compound
2) Promising preclinical studies
3) Phase 1 studies, PK/PD, interaction
4) Phase 2a study with no efficacy endpoint
5) Discussions with the FDA, and FDA Division heads interject irrelevant and meaningless "suggestions" for demonstrating efficacy
5) Phase 2b "proof of concept" study, that in fact is barely positive
5.1) Senio executive leadership decided to move ehad because of good "portfolio management"
6) More discussion with the FDA, and almost unattainable, clinically meaningless inclusion/exclusion criteria are demanded. Additionally, rating instruments are selected that no one outside research is familiar with, nor demonstrate good inter-rater reliability amongst sites
7) Phase 3 program goes down in flames
7.1) If Eli Lilly, trumpet your "post-hoc" 34% reduction in cognitive decline, and move into a single phase 3 trial bigger than your original two phase 3 studies combined
8) Company "takes a charge" for R&D failure, all the while simply conducting trials in an area of high need enhances your "portfolio" and therefore stock value
9) Gracefully exit having made a 50% ROI
10) Rinse and repeat in another disease area

Permalink to Comment

3. lcollia on February 25, 2014 3:01 AM writes...

It seems very interesting, BUT what a shame that the webinars will happen at 2PM EST, i.e. at 8PM in Europe!!!

Permalink to Comment

4. Anonymous on February 25, 2014 4:15 AM writes...

@1: CNS = Crazy Noise-to-Signal

Permalink to Comment

5. interested on February 25, 2014 4:35 AM writes...

Do you have to watch these live?

Permalink to Comment

6. Chemjobber on February 25, 2014 9:20 AM writes...

No, traditionally ACS Webinars have been posted to YouTube about a week or two after they're recorded live. However, you may have to watch the ACS Webinars YouTube channel in order to catch the release.

Permalink to Comment

7. interested on February 25, 2014 12:36 PM writes...

Thanks. In the UK, that's too close to dinner time.

Permalink to Comment

8. Anonymous on February 26, 2014 4:01 AM writes...

Closer to tea time surely? ;)

Permalink to Comment

9. petros on February 26, 2014 8:11 AM writes...

re #8

UK terminology for meals (except breakfast) is a class/regional thing

midday = lunch (South/upper class) or dinner (North)
evening = dinner/supper and tea respectively

Permalink to Comment

10. Anonymous on February 27, 2014 2:59 PM writes...

Hi Derek,

Our med chem group was enjoying your discussion when we were disconnected following the poll. Any idea what happened? Looking forward to downloading the webinar recording and attending future sessions.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
A New Route to Spiro Heterocycles
A New Effect From JAK Inhibition
Ambition From Recursion
More on the "Unclick" Fraud Case at Texas
How Many Things Can Be Enzymes, Anyway?
A Slight Cubist Complication
Amazing, Up to a Point
Merck Buys Cubist